Please upgrade your browser.
Archexin for Cancer: A first-in-class AKT Inhibitor for glioblastoma, pancreatic, stomach, ovarian, & renal cell cancers, as well as other solid tumors. Incredibly, the FDA granted orphan drug status in all 5 tumor types for this drug. It significantly reduces production of AKT protein via inhibition of AKT mRNA.
This debate is reflected in the committee's examination of which possible PERC-related cancer -- leukemia, liver tumors, or kidney cancer -- provides the strongest data for EPA to estimate its cancer potential.
Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma
In metastatic renal cell carcinoma combinations of interferon alfa-2a, interleukin-2, and fluorouracil produce higher response rates and longer progression-free survival than do single agents. We aimed to compare overall survival in patients receiving combination treatment or interferon alfa-2a.
Percutaneous imaging guided tumor ablation has an increasingly prominent role as minimally invasive treatment for renal tumors. Precise cryoprobe placement is essential for successful ablation. CT-Nav(R) is a novel stereotactic surgical navigation system with the potential to achieve precise percutaneous cryoprobe placement while decreasing radiation exposure compared to conventional computerized tomography guided procedures.
Trial patient and cancer sufferer Dave Saunders says a drug banned by UK's NICE saved his life.
A division bench of Delhi high court on Tuesday dismissed Bayer's appeal against a judgment on an anti-cancer drug delivered by Justice Ravindra Bhat in August last year. The judgement rejected Bayer's attempt to introduce patent linkage system in the country a policy change, through a court direction. Patent linkage is against public health interests as it will delay the entry of cheaper generic medicines into the market and keep medicines out of reach of those who need them.
Terminally ill patients are being penalised for having rare conditions charities have warned after a kidney cancer medication was ruled too expensive for the NHS.
US HIFU Partners with Riverside Research Institute to Add Cancer Targeting Technology to HIFU Treatment
US HIFU, a worldwide leader in the development, distribution and use of minimally invasive high intensity focused ultrasound (HIFU) technologies, announced today its exclusive partnership with Riverside Research Institute (RRI) to develop and test an ultrasonic method of prostate imaging and treatment that combines advanced tissue-type imaging with ultrasound energy from the Sonablate(R) 500 medical device.
The first patient in the study is now expected to receive treatment through the National Health Service.
The U.K.s health-cost regulator rejected Novartis AGs tumor treatment Afinitor for advanced kidney cancer in a draft ruling that is likely to curtail its use among publicly insured patients.
|Powered by NeonCRM|